Key features and details
- Expression system: Escherichia coli
- Purity: > 98% SDS-PAGE
- Endotoxin level: < 0.100 Eu/µg
- Active: Yes
- Suitable for: SDS-PAGE, HPLC, ELISA, WB
Product nameRecombinant human IL-31 protein
See all IL-31 proteins and peptides
Biological activityMeasured by its ability to induce STAT3 activation in Human U87 cells.
Purity> 98 % SDS-PAGE.
Greater than 98% by SDS-PAGE gel and HPLC analyses
Endotoxin level< 0.100 Eu/µg
Expression systemEscherichia coli
Protein lengthFull length protein
SequenceSHTLPVRLLR PSDDVQKIVE ELQSLSKMLL KDVEEEKGVL VSQNYTLPCL SPDAQPPNNI HSPAIRAYLK TIRQLDNKSV IDEIIEHLDK LIFQDAPETN ISVPTDTHEC KRFILTISQQ FSECMDLALK SLTSGAQQAT T
Predicted molecular weight16 kDa
Amino acids24 to 164
Our Abpromise guarantee covers the use of ab106619 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -80°C. Avoid freeze / thaw cycle. For long term storage it is recommended to add a carrier protein on reconstitution (0.1% HSA or BSA).
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ReconstitutionThe lyophilised product should be stored at -20oC till use. Once the product has been reconstituted according to the CoA, this can be diluted further in a chosen aqueous buffer containing a carrier protein, such as 0.1% BSA and stored in working aliquots at -20oC for at least 3 months
- IL 31
FunctionActivates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR. IL31 may function in skin immunity.
Tissue specificityDetected at low levels in testis, bone marrow, skeletal muscle, kidney, colon, thymus, small intestine and trachea.
- Information by UniProt
Whole cell lysate prepared from human eosinophil granulocytes was loaded at 500000 cells.
5-16% gel run under reducing, denaturing conditions.Blocking step performed using 5% BSA for 2 hours at 25°C.
ab106619 used at a 1/200 dilution.Primary antibody used at a 1/100 dilution.
Secondary antibody was an HRP conjugated goat anti-rabbit IgG, used at a 1/200 dilution.The positive control was stimulated with IL-3 (10ng/ml) + IL-5 (10ng/ml) + GM-CSF (10ng/ml) for 30 minutes.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab106619 has not yet been referenced specifically in any publications.